1-20 of 333
tositumomab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Free
CME Clinical Trials & Observations
Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfò, Erel Joffe, Chava Perry, Paolo Ghia
Journal: Blood
Blood (2021) 137 (23): 3165–3173.
https://doi.org/10.1182/blood.2021011568
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Free
Radhakrishnan Ramchandren, MD, Peter Johnson, MDFRCP, Nilanjan Ghosh, MD PhD, Jia Ruan, MD PhD, Kirit M. Ardeshna, MA, MD FRCP, FRCPath, Roderick Johnson, MD, Gregor Verhoef, MD PhD, David Cunningham, MD FRCP, FMedSci, Sven de Vos, MD PhD, Shireen Kassam, MD, Luis Fayad, MD, John Radford, Sarah Bailly, MD, Fritz Offner, MD, David Morgan, MD, Javier Munoz, MD, Jerry Ping, PhD, Kevin Kwei, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Andre Goy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 761.
https://doi.org/10.1182/blood-2019-121521
Published: 2019
Journal Articles

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States

Free
Scott F. Huntington, MD MPH, Pamela R. Soulos, Paul M. Barr, MD, Ryan Jacobs, MD, Frederick Lansigan, MD, Oreofe O. Odejide, MD MPH, Lee S. Schwartzberg, MD, Amy J. Davidoff, PhD MS, Cary P Gross, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 797.
https://doi.org/10.1182/blood-2019-122054
Published: 2019
Journal Articles

Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP

Free
Christopher Rushton, BSc, Sarah E Arthur, BSc, Miguel Alcaide, PhD, Matthew Cheung, BSc, Nicole Thomas, BSc, Laura K Hilton, PhD, Neil R Michaud, Scott Daigle, Jordan Davidson, BSc, Kevin R Bushell, BSc, MSc, Stephen Yu, MSc, Michael D. Jain, MD PhD, Lois E. Shepherd, Michael Crump, MD FRCPC, Koren Kathleen Mann, PhD, John Kuruvilla, MD, Sarit Assouline, MD, Kirstie Cleary, PhD, Mark S Cragg, Prof, David W. Scott, MBChB, PhD, Nathalie Johnson, MD, Ryan D. Morin, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 921.
https://doi.org/10.1182/blood-2019-127399
Published: 2019
Journal Articles

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Free
Michael L. Wang, MD, Javier Munoz, MD, Andre Goy, MD, Frederick L. Locke, MD, Caron A. Jacobson, MD MMSc, Brian T. Hill, MD, John M. Timmerman, MD, Houston Holmes, MD, Samantha Jaglowski, MDMPH, Ian W. Flinn, MD PhD, Peter A. McSweeney, MD, David B. Miklos, MD PhD, John M. Pagel, MD PhD DSc, Marie Jose Kersten, MD PhD, Weimin Peng, MS, Lianqing Zheng, PhD, John M. Rossi, MS, Rajul K. Jain, MD, Arati V. Rao, MD, Patrick M Reagan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 754.
https://doi.org/10.1182/blood-2019-126064
Published: 2019
Journal Articles

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Free
Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Kamal Bouabdallah, MD, Guillaume Cartron, Olivier Casasnovas, MD, Thomas Gastinne, MD, Patrice Chevallier, MD, Cédric Rossi, MD PhD, Emmanuelle Tchernonog, MD, Rory McCulloch, FRCPath, MRCP, MBBS, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule
Journal: Blood
Blood (2019) 134 (Supplement_1): 1530.
https://doi.org/10.1182/blood-2019-125681
Published: 2019
Journal Articles

Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL)

Free
Ravi Dashnamoorthy, PhD, Saheli Sarkar, PhD, Afshin Beheshti, PhD, Maisarah Mokhtar, B.S, Tali Konry, PhD, Michael Levin, PhD, Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 1511.
https://doi.org/10.1182/blood-2019-126539
Published: 2019
Journal Articles

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Free
Mark Roschewski, MD, Raquel Izumi, PhD, Ahmed Hamdy, MD, Manish R. Patel, MD, Hendrik-Tobias Arkenau, MD PhD, Sven de Vos, MD PhD, Patrick M Reagan, MD, Pier Luigi Zinzani, MD PhD, Andrew Davies, MD PhD, John M Pagel, MD PhD, Julie M Vose, MDMBA, Bojena Bitman, Graham Brock, PhD, Edwin Clark, PhD, Melanie M. Frigault, PhD, Joseph Ware, PhD, Buyue Yang, MD PhD, Wyndham Wilson, MD, Louis Staudt, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2869.
https://doi.org/10.1182/blood-2019-125939
Published: 2019
Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Free
Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5244.
https://doi.org/10.1182/blood-2019-124326
Published: 2019
Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Free
Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5245.
https://doi.org/10.1182/blood-2019-126455
Published: 2019
Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Free
Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5268.
https://doi.org/10.1182/blood-2019-123466
Published: 2019
Journal Articles

Outcomes and Toxicities of Ibrutinib in Marginal Zone Lymphoma: A Retrospective Cohort Study at a Single Institution

Free
David M. Weiner, BA, Nathaniel D. Robinson, MD, Steven M. Bair, MD, Hatcher J. Ballard, BS, Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, Elise A. Chong, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5250.
https://doi.org/10.1182/blood-2019-128556
Published: 2019
Journal Articles

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Free
Nathan H. Fowler, MD, Judith Trotman, MBChB, FRACP, FRCPA, Rebecca Auer, MRCP, FRPath, PhD, Christopher R. Flowers, MD MS, William F. Reed, MD, Elena Ivanova, PhD, Jane Huang, MD, Pier Luigi Zinzani, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5252.
https://doi.org/10.1182/blood-2019-122628
Published: 2019
Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Free
Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3035.
https://doi.org/10.1182/blood-2019-123419
Published: 2019
Journal Articles

Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma

Free
Michael D. Jain, MD PhD, Anca Prica, MD, Ryan D. Morin, PhD, Vishal Kukreti, MD, Robert Kridel, MDMPH,PhD, Rob C. Laister, PhD, Li Meng, Christopher Rushton, Miguel Alcaide, Rashmi S. Goswami, MD PhD, Jan Delabie, MD PhD, Jessica Weiss, Tony Panzarella, M.Sc., P.Stat, Michael Crump, MD, David W. Scott, MBChB, PhD, John Kuruvilla, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2027.
https://doi.org/10.1182/blood-2019-131818
Published: 2019
Journal Articles

Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia

Free
Jeff P. Sharman, MD, John M Burke, MD, Habte A Yimer, MD, Michael A. Boxer, MD, Sunil Babu, MD, Jia Li, PhD, Yong Mun, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4317.
https://doi.org/10.1182/blood-2019-122482
Published: 2019
Journal Articles

A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation

Free
Jennifer R Brown, MD PhD, Barbara F. Eichhorst, MD, Paolo Ghia, MD PhD, Arnon P. Kater, MD PhD, Jianyong Li, MD, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 4318.
https://doi.org/10.1182/blood-2019-123057
Published: 2019
Journal Articles

Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells after Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data

Free
Rainer Boxhammer, Frank Striebel, Roland Baumgartner, Jan Endell
Journal: Blood
Blood (2019) 134 (Supplement_1): 5061.
https://doi.org/10.1182/blood-2019-128613
Published: 2019
Journal Articles

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Free
Stephen Opat, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, William Reed, MD, Chris Tankersley, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5256.
https://doi.org/10.1182/blood-2019-122629
Published: 2019
Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Free
Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4312.
https://doi.org/10.1182/blood-2019-122491
Published: 2019